Nucleus Software Exports Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
May 26, 2023 at 02:47 am EDT
Share
Nucleus Software Exports Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported revenue was INR 2,159.3 million compared to INR 1,593.9 million a year ago. Net income was INR 676.5 million compared to INR 182.9 million a year ago. Basic earnings per share from continuing operations was INR 25.27 compared to INR 6.67 a year ago. Diluted earnings per share from continuing operations was INR 25.27 compared to INR 6.67 a year ago.
For the full year, revenue was INR 6,685.2 million compared to INR 5,318.5 million a year ago. Net income was INR 1,277.9 million compared to INR 409.1 million a year ago. Basic earnings per share from continuing operations was INR 47.73 compared to INR 14.28 a year ago. Diluted earnings per share from continuing operations was INR 47.73 compared to INR 14.28 a year ago.
Nucleus Software Exports Limited is a provider of lending and transaction banking products to the financial services industry. The Company is engaged in the business of development and marketing of software, product, and software services for business entities in the banking and financial services (BFS) vertical having its operating units located in Noida, Uttar Pradesh. It operates in seven geographical segments: India, Far East, Southeast Asia, Europe, Middle East, Africa, and Australia. Its two flagship products include FinnOne Neo and FinnAxia. FinnOne Neo suite is an end-to-end solution for lending businesses. FinnAxia suite offers an enterprise solution for the transaction banking operations of corporate banks. It provides various lending, such as FinnOne Neo retail lending, FinnOne Neo corporate lending, FinnOne Neo digital channels, and Nucleus lending analytics. Its transaction banking includes advisory services and FinnAxia cash and liquidity management.
NUCLEUS SOFTWARE EXPORTS LIMITED 
